In the same way, strategies to inhibit RAS downstream effectors or synthetic lethality approaches failed to show clinical efficacy (68, 71–74) due to either feedback activation of RAS upstream effectors or tumor heterogeneity regarding KRAS synergistic oncogenic dependencies (75). The gene discussed is KRAS; the disease is neoplasm.